Dihydropyridines

09/01/1998 - "[Choice of first line treatment for arterial hypertension: should one avoid dihydropyridines in diabetic patients?]."
01/01/2006 - "The purpose of this study was to assess the clinical utility of the smoothness index (SI) and normalized SI (SIn), measures of duration and homogeneity of blood pressure (BP) reduction, during an observation period without antihypertensive therapy followed by a treatment period using dihydropyridines (DHP) in 54 newly diagnosed and previously untreated subjects (age 46.9 +/- 9.1 years) with essential hypertension. "
01/01/2011 - "All dihydropyridines attenuated the increases in aortic MMP-2 levels and activity associated with 2K1C hypertension. "
01/01/2010 - "Their decades-long track record of safe use in the treatment of hypertension makes dihydropyridines particularly attractive as a therapeutic tool in PD."
01/01/2005 - "[Dihydropyridines for treatment of arterial hypertension]."

06/01/2006 - "FEVER study: a trial further supporting the concept of a blood pressure-independent stroke protective effect by dihydropyridines."
06/01/2007 - "The priority that we give to diuretic therapy is based on the evidence that this class confers good prevention against both heart failure and strokes, which is not the case for all AT1-inhibitors and dihydropyridines. "
12/01/1993 - "Dihydropyridines have a beneficial effect in the control of hypertension in stroke patients."
04/01/2009 - "In patients with coronary artery disease, long-acting CCBs (either dihydropyridines or nondihydropyridines), were associated with a reduction in the risk of stroke, angina pectoris, and heart failure, with similar outcomes for other cardiovascular events as the comparison group."
06/01/2004 - "However, in primary or secondary stroke prevention trials in patients with low cardiac risk, b-blockers and angiotensin-converting enzyme inhibitors (ACEIs), which decrease Ang II formation, seem to be less protective than thiazides and dihydropyridines, which increase Ang II. When compared with a beta-blocker, an Ang II-increasing AT1-receptor blocker better protects against stroke but not against cardiac events, whereas an ACEI gives the same protection against both cardiac and cerebral events. "

03/01/1993 - "In contrast, in hypertensive patients with heart failure the administration of dihydropyridines improves systolic performance. "
06/01/2007 - "The priority that we give to diuretic therapy is based on the evidence that this class confers good prevention against both heart failure and strokes, which is not the case for all AT1-inhibitors and dihydropyridines. "
10/01/2001 - "Nonetheless, beta-blockers are preferred in postinfarct patients or in those with heart failure or unstable angina (a contraindication to dihydropyridines in the absence of beta-blockade). "
02/01/1990 - "As a class, the dihydropyridines exert reasonably distinct hemodynamic changes that may be of particular importance in the treatment of hypertension, cardiac failure, and regurgitant valvular lesions. "
06/01/1991 - "Its cardiovascular profile suggests that elgodipine may not only be useful in the treatment of cardiovascular disorders for which other dihydropyridines are already in use, but also in mild chronic heart failure."

04/06/1998 - "Short acting dihydropyridines (nifedipin) appear to be harmful by patients after myocardial infarction which is caused by the reflex sympathetic response to the predominant vasodilation. "
12/01/2006 - "Although the efficacy of CCBs as antihypertensive agents has been adequately demonstrated, there have been concerns regarding the use of short acting dihydropyridines after acute myocardial infarction. "
07/01/1996 - "Verapamil, but not dihydropyridines, decreases mortality after myocardial infarction in patients without congestive heart failure. "
06/20/1996 - "Thus, the role of calcium antagonists in the treatment of myocardial infarction is reviewed, and the differences among the 3 classes of calcium channel antagonists, phenylalkylamines, dihydropyridines, and benzothiazepines, are discussed."
09/01/1998 - "The use of dihydropyridines as first-line antihypertensive drugs in Type 2 (non-insulin-dependent) diabetic subjects has recently been challenged by several clinical trials that found increased risk of cardiovascular events (sudden death and myocardial infarction). "

03/01/1993 - "The dihydropyridines did not influence seizures elicited by maximal electroshock (MES). "
01/01/1990 - "These results indicate that Ca2+ channels modulated by dihydropyridines play a facilitating role in ECS-induced seizures. "
09/01/1987 - "Effect of dihydropyridines and diphenylalkylamines on pentylenetetrazol-induced seizures and cerebral blood flow in cats."
04/01/2004 - "Lipophilic 4-imidazoly-1,4-dihydropyridines: synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure."
03/01/1993 - "Anticonvulsant properties of calcium channel blockers in mice: N-methyl-D-,L-aspartate- and Bay K 8644-induced convulsions are potently blocked by the dihydropyridines."